A Phase I Study of Polyethylene Glycol Loxenatide in Patients With Type 2 Diabetes
Status:
Completed
Trial end date:
2013-04-01
Target enrollment:
Participant gender:
Summary
Polyethylene Glycol Loxenatide (PEX168) is a new human glucagon-like peptide 1 (GLP-1)
analogue that created on the basis of the Exenatide and modified by polyethylene glycol
(PEG).
This study aims to evaluate whether the titration mode of administration could reduce the
incidence of adverse reactions of PEX168, also decided to observe long-term continuous
administration of PK/PD correlation.
Phase:
Phase 1
Details
Lead Sponsor:
Jiangsu HengRui Medicine Co., Ltd.
Collaborator:
People's Liberation Army General Hospital of Chengdu Military Region